Introducing CITIDARON®
How CITIDARON® works
When to use CITIDARON®?
Why use CITIDARON®?
How to use CITIDARON®?
CITIDARON® prescribing considerations
INTRODUCING CITIDARON®
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking1
The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use 1
- Research shows that smokers who get help and use proven methods like behavioural support and medications are more likely to successfully quit 2
- Each attempt to quit smoking is vital, as every effort brings smokers one step closer to permanently overcoming this habit.
- CITIDARON® is a 25 day treatment course1
- CITIDARON® does not contain nicotine and has a favourable tolerability profile
References
1. Cytisine Summary of Product Characteristics, Consilient Health 2023.
2. HTA of smoking cessation interventions HSE (2017) Available at: https://www.hiqa.ie/reports-and-publications/health-technology-assessment/
hta-smoking-cessation-interventions [Accessed November 2023].
Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760
Healthcare professionals are asked to report any suspected adverse reactions. To report an adverse event or a product complaint about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or 012057766. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting form and information can be found at http://www.hpra.ie then click on “report an issue”.
IE-CH-1559 Date of Preparation April 2024